WALTHAM, Mass., Nov. 6, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that CEO John Kollins will present a corporate overview and update at the Rodman and Renshaw 10th Annual Healthcare Conference on Monday, November 10th, at 4:05 p.m. EST (1:05 p.m. PST), in the Palace Hotel in New York City, N.Y.
Mr. Kollins will also present a corporate overview and update at the Lazard Capital Markets 5th Annual Healthcare Conference on Tuesday, November 18th, at 2:10 p.m. EST (11:10 a.m. PST), in the St. Regis Hotel in New York City, N.Y.
A live and archived webcast of each presentation can be accessed for 30 days following the presentations by clicking on the Investor Center tab at www.oxigene.com.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The company's major focus is developing VDAs that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969